Dexmedetomidine hydrochloride is a Small Molecule owned by Orion, and is involved in 82 clinical trials, of which 68 were completed, 13 are ongoing, and 1 is planned.
Dexmedetomidine Hydrochloride is the hydrochloride salt form of dexmedetomidine, an imidazole derivate and active d-isomer of medetomidine with analgesic, anxiolytic and sedative activities. Dexmedetomidine selectively binds to and activates presynaptic alpha-2 adrenoceptors located in the brain, thereby inhibiting the release of norepinephrine from synaptic vesicles. This leads to an inhibition of postsynaptic activation of adrenoceptors, which inhibits sympathetic activity, thereby leading to analgesia, sedation and anxiolysis.
The revenue for Dexmedetomidine hydrochloride is expected to reach a total of $85m through 2027. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dexmedetomidine hydrochloride NPV Report.
Dexmedetomidine hydrochloride Overview
Dexmedetomidine Hydrochloride (Precedex, Dexdor, Xamdex) is a sedative agent. It is formulated as concentrate solution, injectable solution and powder for solution for intravenous route of administration. Dexmedetomidine Hydrochloride is used for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. It is also indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures. Dexmedetomidine (DEX-IN, DEX-TD, DEX-SL) is under development as a non-intravenous formulation for the treatment of cancer pain, peri procedural pain and acute pain in adult patients undergoing hallux valgus (Bunion) surgery. It was also under development for the treatment of post operative pain and chronic lower back pain.
Orion develops, manufactures and markets human and veterinary pharmaceuticals, and active pharmaceutical ingredients (APIs). Its products include pharmaceuticals for the treatment of central nervous system disorders, cancer, and respiratory diseases. The company’s pipeline encompasses investigational candidates for the treatment of amyotrophic lateral sclerosis, Parkinson’s disease, chronic obstructive pulmonary disease, and various cancer types. Orion’s client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics, and laboratories. The company sells its products in European markets through own sales network and in international markets through several partners and distributors. Orion is headquartered in Espoo, Finland.
The company reported revenues of (Euro) EUR1,041 million for the fiscal year ended December 2021 (FY2021), a decrease of 3.4% over FY2020. In FY2021, the company’s operating margin was 23.4%, compared to an operating margin of 26% in FY2020. In FY2021, the company recorded a net margin of 18.6%, compared to a net margin of 20.4% in FY2020. The company reported revenues of EUR491.8 million for the third quarter ended September 2022, an increase of 73.4% over the previous quarter.
Quick View – Dexmedetomidine hydrochloride
|Highest Development Stage|